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Abstract
Background Psychiatric sequelae after traumatic brain injury (TBI) are common and may impede recovery. We aimed to 
assess the occurrence and risk factors of post-injury psychotropic medication use in intensive care unit (ICU)-treated patients 
with TBI and its association with late mortality.
Methods We conducted a retrospective multi-centre observational study using the Finnish Intensive Care Consortium data-
base. We included adult TBI patients admitted in four university hospital ICUs during 2003–2013 that were alive at 1 year 
after injury. Patients were followed-up until end of 2016. We obtained data regarding psychotropic medication use through 
the national drug reimbursement database. We used multivariable logistic regression models to assess the association between 
TBI severity, treatment-related variables and the odds of psychotropic medication use and its association with late all-cause 
mortality (more than 1 year after TBI).
Results Of 3061 patients, 2305 (75%) were alive at 1 year. Of these, 400 (17%) became new psychotropic medication users. 
The most common medication types were antidepressants (61%), antipsychotics (35%) and anxiolytics (26%). A higher 
Glasgow Coma Scale (GCS) score was associated with lower odds (OR 0.93, 95% CI 0.90–0.96) and a diffuse injury with 
midline shift was associated with higher odds (OR 3.4, 95% CI 1.3–9.0) of new psychotropic medication use. After adjusting 
for injury severity, new psychotropic medication use was associated with increased odds of late mortality (OR 1.19, 95% CI 
1.19–2.17, median follow-up time 6.4 years).
Conclusions Psychotropic medication use is common in TBI survivors. Higher TBI severity is associated with increased 
odds of psychotropic medication use. New use of psychotropic medications after TBI was associated with increased odds of 
late mortality. Our results highlight the need for early identification of potential psychiatric sequelae and psychiatric evalu-
ation in TBI survivors.
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Introduction
Survivors of traumatic brain injury (TBI) and intensive care 
unit (ICU) treatment suffer from long-term neurological, 
psychiatric and social burden, in spite of favourable func-
tional recovery [10, 22, 26, 37–39]. Patients with TBI may 
suffer from various psychiatric problems, such as depres-
sion, bipolar affective disorder and anxiety disorders, which 
are likely to impede recovery [12, 17, 29, 33, 37]. In general, 
patients suffering from any trauma seem to be susceptible 
to psychiatric problems following ICU admission [35]. In 
addition, a significant proportion of patients with TBI have 
psychiatric comorbidities prior to injury, the three most 
common being substance use disorder, major depressive 
disorder and anxiety [39]. Indeed, psychiatric comorbidities 
are among the strongest predictors of late mortality (death 
1 year or later after discharge) among patients with TBI [4].
In recent years, there has been an increase in the use of 
psychotropic medications among the general population in 
many high-income countries. In Finland, the prevalence of 
psychotropic medication use was 18% in the adult popula-
tion in 2013 [40]. Of all psychotropic medications, anti-
depressants is the most common medication used among 
TBI patients [2]. In Europe between the years 2000 and 
2010, the prevalence of antidepressant use increased from 
3.7 to 7.2% [24]. In parallel, the global incidence of TBI 
is increasing [14]. Thus, given the negative impact of psy-
chiatric sequelae on recovery of patients with TBI, there is 
a need to understand the complex interplay between pre- 
and post-injury psychotropic medication use and TBI care.
Accordingly, we designed the current study to gain data 
on the prevalence of psychotropic medication use, as a proxy 
of psychiatric disorders, among patients with TBI treated in 
the ICU. We set out to study whether certain injury types, 
or any particular clinical course, would associate with the 
need for psychotropic medications among TBI survivors. We 
further studied whether new or previous use of psychotropic 
medications was associated with in increased risk for late 
all-cause mortality in 1-year survivors. We hypothesized that 
(1) the use of psychotropic medications would be common 
both pre- and post-TBI, (2) that higher TBI severity would 
increase the use of psychotropic medication in survivors and 
(3) that TBI survivors using psychotropic medications would 
have an increased risk for late mortality.
Methods and materials
The ethics committee of Helsinki University Hospi-
tal (194/13/03/14 §97), the Finnish National Insti-
tute for Health and Welfare (THL/713/5.05.01/2014 
and THL/1298/5.05.00/2019), Statistics Finland (TK-
53–1047-14), the Social Insurance Institution of Finland 
(Kela 23/522/2018), the Office of the Data Protection 
Ombudsman (Dnro 2713/402/2016 28.10.16) and all the 
participating university hospitals’ research committees 
approved this study. The study adhered to the Strengthen-
ing the Reporting of Observational studies in Epidemiol-
ogy (STROBE) guidelines. We retrieved data on mortal-
ity from the Finnish population register on December 31, 
2016 (available for all Finnish residents).
Study design and population
We performed a multi-centre retrospective observational 
study using data that were prospectively collected to the 
Finnish Intensive Care Consortium (FICC) database. The 
FICC database is a nationwide database including all ICU-
treated patients from the majority of all Finnish ICUs [34]. 
In Finland, all specialized tertiary intensive care of patients 
with TBI is centralized to five university hospital ICUs. 
Four of these ICUs, covering approximately two-thirds of 
the population in Finland, participate in the FICC. From 
these four tertiary ICUs, we included all adult TBI patients 
(age ≥ 18 years) admitted between January 1, 2003, and 
December 31, 2013 (readmissions excluded). TBI patients 
were identified by Acute Physiology and Chronic Health 
Evaluation (APACHE) III diagnostic codes and the diagno-
ses were manually verified by screening health records and 
reviewing primary head computer tomography (CT) scans 
[31]. Patients were excluded, if no CT was available, Glas-
gow Coma Scale (GCS) or pre-admission functional status 
was missing.
Definition of covariates
ICU-related variables were retrieved from the FICC data-
base. The GCS score is defined according to the APACHE 
II definition as the worst measured GCS score during the 
first ICU day [20]. For intubated and/or sedated patients, 
the last reliable GCS score preceding sedation is used. The 
FICC uses a modified version of the World Health Organiza-
tion/Eastern Cooperative Oncology Group (WHO/ECOG) 
classification for pre-admission functional status (fit for 
work or equal, unfit for work but independent in self-care, 
partially dependent in self-care, totally dependent in self-
care) [27]. We classified all admission CT scans according 
to the Marshall CT classification [25]. We defined a signifi-
cant chronic comorbidity according to the APACHE II and 
Simplified Acute Physiology Score (SAPS) II [20, 23]. We 
defined Intracranial Pressure (ICP) monitoring through the 
Therapeutic Intervention Scoring System (TISS) 76 that is 
routinely collected for the FICC database [19]. We used the 
NOMESCO Classification of Surgical Procedures Finland 
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(NCSP-F) for the definition of external ventricular drain 
(EVD, NCSP-F code AAF00), craniotomy for hematoma 
evacuation (NCSP-F code AAD00, AAD05, AAD15) and 
for decompressive craniectomy (NCSP-F code AAK80).
Psychotropic medication purchases
In Finland, patients get physician-prescribed medication, 
including psychiatric medication, reimbursed by the Social 
Insurance Institution with a maximum out-of-pocket pay-
ment of roughly 600 euros per calendar year. After the out-
of-pocket ceiling is reached, patients pay 2.50 euros per 
medication and per purchase regardless of the cost.
We obtained data on purchased psychotropic medication 
from the Social Insurance Institution from January 1, 2003, 
to December 31, 2013. We defined psychotropic medica-
tion as an Anatomical Therapeutic Chemical (ATC) clas-
sification system code of N05A-C* (N05A = antipsychotics, 
N05B = anxiolytics, N05C = hypnotics and sedatives) and 
N06A-C* (N06A = antidepressants, N06B = psychostimu-
lants, N06C = psycholeptics and psychoanaleptics in com-
bination, excluding N06D*, anti-dementia drugs) [40]. We 
considered psychotropic medication use if the patient pur-
chased the medication at least two times. We defined start 
of psychotropic medication use at the date of first purchase. 
We separately classified according to pre-TBI use and post-
TBI use.
Statistical methods
We used SPSS Statistics 25.0 for mac OS (IBM Corp, 
Armonk, NY) and Stata Statistical Software for macOS 
(StataCorp LP, College Station, TX) for the statistical 
analyses.
We compared categorical data between groups using a 
two-sided χ2 test. We tested continuous data for skewness. 
We present normally distributed data as means with standard 
deviations (SD) and non-parametric data as medians with 
interquartile range (IQR). We compared normally distributed 
data between groups using a t-test and non-parametric data 
using a Mann–Whitney U test.
We tested the association between risk factors and the 
odds of use of psychotropic medication using multivariable 
logistic regression models. In the logistic regression models, 
we adjusted for age, gender, GCS score, chronic comorbid-
ity, WHO/ECOG classification, Marshall CT classification 
and a modified SAPS II (excluding age, GCS score and 
chronic comorbidity) [31].
We tested the association between pre-TBI psychotropic 
medication use and 1-year mortality and between post-TBI 
psychotropic medication use and late mortality (in 1-year 
survivors) using logistic regression analysis, adjusting for 
the aforementioned factors. We defined late mortality as all-
cause mortality that happened later than 1 year after TBI, 
as most of the death attributable to TBI occurs in the first 
year [1].
Results
Of 3061 patients, 1195 (39%) had a history of psycho-
tropic medication use prior to the TBI (Fig. 1). Of the 3061 
patients, 2305 (75%) were alive 1 year after the TBI. Of 
these, 866 patients (38%) had a history of psychotropic med-
ication use prior to TBI, 400 patients (17% of all survivors) 
Fig. 1  Flow chart. Abbre-
viations: TBI, traumatic brain 
injury; FICC, Finnish Intensive 
Care Consortium; CT, com-
puterized tomography; GCS, 
Glasgow Coma Scale 
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were prescribed a psychotropic medication after TBI and 
1039 patients (45%) had no prior or new history of psycho-
tropic medication use.
Median time from first psychotropic medication purchase 
to TBI was 4.0 years (IQR 2.0–6.4) for those with a his-
tory of psychotropic medication use prior to TBI. Median 
time from TBI to first psychotropic medication purchase 
was 0.6 years for those without a history of prior use (IQR 
0.2–1.5 years).
Patients with a history of pre-TBI use of psychotropic 
medication (N = 1195) had been less frequently fit for work 
(51% vs. 68%), were more often female (29% vs. 19%) and 
had more severe chronic comorbidities (11% vs. 7%) than 
patients without a pre-TBI history of psychotropic medica-
tion use (Table 1).
One-year survivors with a new post-TBI psychotropic 
medication use had lower GCS scores (median 9 vs. 12), 
had been less frequent fit for work (67% vs. 76%), more 
often underwent craniotomy for mass lesion (42% vs. 31%), 
were more often mechanically ventilated (73% vs. 56%), had 
higher SAPS II scores (34 vs. 28) and more often a mass 
lesion on the admission head CT scan (41% vs. 35%) than 
1-year survivors without a need for psychotropic medication 
(Table 2).
In patients with pre-TBI psychotropic medica-
tion use, the most common psychotropic drugs were 
Table 1  Baseline characteristics and treatment of traumatic brain injury patients
* A modified World Health Organization/Eastern Cooperative Oncology Group classification system implemented by the Finnish Intensive Care 
Consortium
† Any chronic comorbidity according to APACHE II or to SAPS II
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; DI, diffuse injury; GCS; Glasgow Coma Scale; EML/NEML, evacu-
ated/non-evacuated mass lesion; LOS, length of stay; ICP, intracranial pressure; ICU, intensive care unit; SAPS, Simplified Acute Physiology 
Score; TBI, traumatic brain injury
Variables All patients
(N = 3061)
Pre-TBI psychotropic medi-
cation use (N = 1195)
No pre-TBI psychotropic 
medication use (N = 1866)
p-value
Age, median (IQR) 56 (41, 67) 57 (45, 68) 54 (38, 66)  < 0.001
  18–40 years 745 (24%) 226 (19%) 519 (28%)  < 0.001
  41–64 years 1434 (47%) 611 (51%) 823 (44%)
  ≥ 65 years 882 (29%) 358 (30%) 524 (28%)
GCS score, median (IQR) 9 (5, 14) 9 (5, 14) 9 (5, 14) 0.92
  3–8 1443 (47%) 557 (47%) 886 (47%) 0.89
  9–12 596 (19%) 236 (20%) 360 (19%)
  13–15 1022 (33%) 402 (34%) 620 (33%)
Females 701 (23%) 348 (29%) 353 (19%)  < 0.001
Pre-admission performance status*
  Fit for work or equal 1872 (61%) 611 (51%) 1261 (68%)  < 0.001
  Unfit for work, but independent in self-care 957 (31%) 451 (38%) 506 (27%)
  Partially dependent in self-care 178 (6%) 99 (8%) 79 (4%)
  Totally dependent in self-care 54 (2%) 34 (3%) 20 (1%)
Significant chronic comorbidity† 261 (9%) 136 (11%) 125 (7%)  < 0.001
SAPS II score, median (IQR) 35 (23, 50) 35 (25, 50) 35 (23, 49) 0.059
Marshall CT classification
  DI I 317 (10%) 114 (10%) 203 (11%)  < 0.001
  DI II 988 (32%) 350 (29%) 638 (34%)
  DI III 287 (9%) 107 (9%) 180 (10%)
  DI IV 45 (1%) 11 (1%) 34 (2%)
  EML V/NEML VI 1424 (47%) 613 (51%) 811 (43%)
Craniotomy and hematoma evacuation 1220 (40%) 532 (45%) 688 (37%)  < 0.001
Decompressive craniectomy 50 (2%) 14 (1%) 36 (2%) 0.11
External ventricular drain 156 (5%) 56 (5%) 100 (5%) 0.41
ICP monitoring 724 (24%) 248 (21%) 476 (26%) 0.003
Mechanical ventilation 2042 (67%) 780 (65%) 1262 (68%) 0.18
LOS ICU, days, median (IQR) 2 (1, 4) 2 (1, 3) 2 (1, 5) 0.005
LOS hospital, days, median (IQR) 6 (3, 11) 5 (3, 19) 6 (3, 11) 0.0012
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antidepressants (70%), hypnotics and sedatives (58%) and 
anxiolytics (47%). Among the 1-year survivors with new 
use of psychotropic medication, antidepressants (61%), 
antipsychotics (35%) and anxiolytics (26%) were the most 
frequently used psychotropic medications. Furthermore, 
27% used multiple psychotropic medications (Supplemen-
tal Table 1).
Risk factors for psychotropic medication
Among the 1439 1-year survivors without a history of 
pre-TBI psychotropic medication use, a higher GCS score 
was associated with lower odds (OR 0.93 per point, 95% 
CI 0.90–0.96) and a diffuse injury IV was associated with 
higher odds (OR 3.37, 95% CI 1.27–9.01, using Marshall 
Table 2  Baseline characteristics and treatment of 1-year survivors of traumatic brain injury patients who had no pre-injury history of psycho-
tropic drug use
Analyses do not include those with a history of psychotropic medication use prior to the index hospitalization
* A modified World Health Organization/Eastern Cooperative Oncology Group classification system implemented by the Finnish Intensive Care 
Consortium
† Any chronic comorbidity according to APACHE II or to SAPS II
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; DI, diffuse injury; GCS; Glasgow Coma Scale; EML/NEML, evacu-
ated/non-evacuated mass lesion; LOS, length of stay; ICP, intracranial pressure; ICU, intensive care unit; SAPS, Simplified Acute Physiology 
Score; TBI, traumatic brain injury
Variables All patients without 
pre-TBI drug use
(N = 1439)
Post-TBI psychotropic 
medication use (N = 400)
No psychotropic medica-
tion use (N = 1039)
p-value
Age, median (IQR) 51 (33, 63) 53 (36, 64) 51 (31, 63) 0.08
  18–40 years 472 (33%) 118 (30%) 354 (34%) 0.25
  41–64 years 639 (44%) 185 (46%) 454 (44%)
  ≥ 65 years 328 (23%) 97 (24%) 231 (22%)
GCS score, median (IQR) 11 (6, 14) 9 (5–13) 12 (7–14)  < 0.001
  3–8 542 (38%) 191 (48%) 351 (34%)  < 0.001
  9–12 309 (21%) 91 (23%) 218 (21%)
  13–15 588 (41%) 118 (30%) 470 (45%)
Females 266 (18%) 84 (21%) 182 (18%) 0.13
Pre-admission performance status*
  Fit for work or equal 1058 (74%) 270 (68%) 788 (76%) 0.003
  Unfit for work, but independent in self-care 330 (23%) 118 (30%) 212 (20%)
  Partially dependent in self-care 41 (3%) 9 (2%) 32 (3%)
  Totally dependent in self-care 10 (1%) 3 (1%) 7 (1%)
Significant chronic comorbidity† 70 (5%) 16 (4%) 54 (5%) 0.34
SAPS II score, median (IQR) 30 (20, 41) 34 (24, 45) 28 (20, 40)  < 0.001
Marshall CT classification
  DI I 179 (12%) 35 (9%) 144 (14%) 0.001
  DI II 587 (41%) 156 (39%) 431 (41%)
  DI III 126 (9%) 35 (9%) 91 (9%)
  DI IV 18 (1%) 11 (3%) 7 (1%)
  EML V/NEML VI 529 (37%) 163 (41%) 366 (35%)
Craniotomy and hematoma evacuation 487 (34%) 169 (42%) 318 (31%)  < 0.001
Decompressive craniectomy 29 (2%) 8 (2%) 22 (2%) 0.66
External ventricular drain 79 (5%) 27 (7%) 52 (5%) 0.19
ICP monitoring 336 (23%) 114 (29%) 222 (21%) 0.004
Mechanical ventilation 869 (60%) 290 (73%) 579 (56%)  < 0.001
LOS ICU, days, median (IQR) 2 (1, 5) 2 (1, 6) 2 (1, 4)  < 0.001
LOS hospital, days, median (IQR) 7 (4, 12) 8 (4–15) 6 (4, 11)  < 0.001
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DI II as the reference) of psychotropic medication use 
(Table 3). In a similar model, using GCS score as a cat-
egorical variable and GCS 13–15 as the reference, GCS 
of 3–8 had an OR of 1.92 (95% CI 1.42–2.59) and GCS 
9–12 had an OR of 1.46 (95% CI 1.05–2.04).
After adjusting for TBI severity, an association 
between craniotomy for hematoma evacuation (OR 1.51, 
95% CI 1.08–2.12) and post-TBI psychotropic medication 
use was found. No association between ICP monitoring, 
EVD or decompressive craniectomy and post-TBI use of 
psychotropics was found (Supplemental Table 2).
Psychotropic medication and mortality
Of 2305 1-year survivors, 547 patients (24%) died dur-
ing follow-up. Median follow-up time was 6.4 years (IQR 
4.3–9.3). New psychotropic medication use (OR 1.60, 
95% CI 1.19–2.17) and a history of pre-TBI psychotropic 
medication use (OR 1.82, 95% CI 1.19–2.17) were associ-
ated with increased odds of late-mortality in 1-year sur-
vivors (Table 4).
Including all patients, pre-TBI use of psychotropic 
medication was not associated with increased odds of 
1-year mortality (Supplemental Table 3).
Discussion
Key findings
In this retrospective multi-centre study, we found that the use 
of psychotropic medication is common both in patients expe-
riencing TBI and among survivors. Four out of ten patients 
with TBI used psychotropic medications pre-injury. Among 
the long-term survivors, three out of ten patients without a 
history of prior psychotropic medication use were prescribed 
a psychotropic medication. These figures are notably higher 
than the use of psychotropic medication (18%) in the whole 
adult population in Finland in 2013 [40]. Thus, patients 
using psychotropic medication are strongly overrepresented 
among ICU-treated patients with TBI. New post-TBI psy-
chotropic medication use was associated with more severe 
TBI and appeared especially common in patients needing 
craniotomy for hematoma evacuation. Importantly, new psy-
chotropic medication use after TBI was associated with an 
increased risk for late mortality.
Few studies have reported the prevalence of pre- and post-
TBI use of psychotropic drugs [13, 21]. However, several 
Table 3  Multivariable logistic regression model showing associa-
tion between patient demographics, markers of traumatic brain injury 
severity and psychotropic medication use in 1-year survivors
Abbreviations: ADL, activities of daily living; CI, confidence interval; 
DI, diffuse injury; EML, evacuated mass lesion; GCS, Glasgow Coma 
Scale; NEML, non-evacuated mass lesion; SAPS, Simplified Acute 
Physiology Score
Variable Odds ratio (95% CI) p-value
Age 1.01 (0.99–1.02) 0.130
Sex
  Male 1.0
  Female 1.31 (0.97–1.77) 0.072
GCS score 0.93 (0.90–0.96)  < 0.001
Significant comorbidity 0.68 (0.38–1.22) 0.196
Pre-admission functional status
  Independent in ADL 1.0
  Dependent in ADL 0.59 (0.30–1.17) 0.135
Modified SAPS II score 1.02 (1.00–1.04) 0.101
Marshall CT class
  DI I 0.71 (0.46–1.08) 0.108
  DI II 1.0
  DI III 0.91 (0.58–1.41) 0.672
  DI IV 3.37 (1.27–9.01) 0.015
  EML V/NEML VI 1.07 (0.81–1.41) 0.635
Table 4  Multivariable logistic regression model showing association 
between use of psychotropic medication and late mortality in 1-year 
survivors
Median follow-up time was 6.4 years (interquartile range 4.3–9.3)
Abbreviations: ADL, activities of daily living; CI, confidence interval; 
DI, diffuse injury; EML, evacuated mass lesion; GCS, Glasgow Coma 
Scale; NEML, non-evacuated mass lesion; SAPS, Simplified Acute 
Physiology Score
Variable Odds ratio (95% CI) p-value
Age 1.05 (1.04–1.05)  < 0.001
Sex
  Male 1.0
  Female 0.58 (0.45–0.76)  < 0.001
GCS score 0.98 (0.95–1.01) 0.172
Significant comorbidity 1.68 (1.15–2.45) 0.008
Pre-admission functional status
  Independent in ADL 1.0
  Dependent in ADL 2.70 (1.76–4.12)  < 0.001
Modified SAPS II score 1.01 (0.99–1.02) 0.530
Marshall CT class
  DI I 0.82 (0.53–1.27) 0.370
  DI II 1.0
  DI III 0.99 (0.64–1.53) 0.953
  DI IV 1.10 (0.39–3.10) 0.861
  EML V/NEML VI 1.72 (1.35–2.19)  < 0.001
Psychotropic medication use
  No 1.0
  Pre-TBI use 1.82 (1.43–2.30)  < 0.001
  New post-TBI use 1.60 (1.19–2.17) 0.002
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studies have shown the abundance of psychiatric sequelae 
and illness among TBI survivors: prevalence of 14–77% for 
depression, 2–17% for bipolar disorder, 3–28% for general-
ized anxiety disorders and 5–28% for substance use have 
been reported [5, 10, 15, 22, 32, 33, 39]. Of patients with 
ICU-treated severe TBI, approximately 30% suffer from 
major depressive disorders and 33% from major personal-
ity change [6]. In comparison, the prevalence of psychiatric 
symptoms in general ICU survivors seems to range between 
17 and 44% [26, 28, 30, 38]. Thus, the high prevalence of 
the use of psychotropic medications in the current study is 
not surprising.
Clinical phenotypes increasing the odds 
of psychotropic prescription
Previous studies have found that the severity of TBI corre-
lates with the incidence of psychiatric illnesses [9]. Studies 
on patients with mild TBI have generally found lower inci-
dences of depression than studies investigating moderate-
to-severe TBI patients [10, 32, 33]. On the contrary, Jorge 
et al. [17] did not find an association between the incidence 
of depression and severity of TBI. It has been speculated that 
a more severe TBI and its related post-traumatic amnesia 
may have a protective role for post-traumatic stress disorder 
(PTSD) and, thus, the relationship between TBI severity 
and depression is not linear [33, 37]. Furthermore, it has 
been proposed that the brain injury area location may be 
more important than general markers of TBI severity such 
as initial GCS or duration of coma in terms of probability 
of depression and other psychiatric disorders [8, 17, 33, 37]. 
Specific locations of lesions in different psychiatric disor-
ders have been found as follows: depression, lower bilateral 
hippocampal volume [16]; mania, lesions in temporal basal 
poles [15]; obsessive-compulsory disorder, orbitofrontal 
cortex, cortex cinguli, nucleus caudatus [3]; psychosis, 
damage in frontal and orbital lobes [11, 36]; alcohol-related 
disorders, prefrontal cortex volume reduction [18]. These 
are in-line with our observations that the more diffuse inju-
ries (Marshall CT class IV) can also damage the parts of 
the brain described earlier, thus specifically causing organic 
psychiatric disorders.
The Marshall CT classification has not been widely used 
to classify radiological findings in previous studies dealing 
with TBI and psychiatric disorders. In the study by Diaz 
et al., Marshall CT classification or presence of traumatic 
subarachnoid haemorrhage (SAH) did not associate with 
post-TBI psychiatric disorder after severe TBI [6]. We found 
that Marshall CT class IV associated with increased odds 
of new psychotropic medication use after TBI. This may be 
interpreted as an association between extensive diffuse brain 
injury and psychiatric sequela.
Interestingly, we found that craniotomy and hematoma 
evacuation associated with increased odds of psychotropic 
medication use, but we did not find a comparable associa-
tion of the combined Marshall classes V and VI and later 
medication use. Considering that the cut off > 25  cm3 for 
the Marshall classes V and VI is purely radiological and 
arbitrary, it is not that surprising. For example, the variable 
craniotomy and hematoma evacuation indirectly represents 
a combination of radiological mass effect, lowered GCS and 
reasonable patient prognosis. Thus, the craniotomy variable 
captures more information than the Marshall classification 
and might be considered as an indicator of a more severe 
brain injury. However, this finding should be interpreted 
with caution as it may be affected by several unmeasured 
factors.
New psychotropic medication use in 1-year survivors 
was associated with increased odds of late mortality, even 
after adjusting for TBI severity. Other risk factors for the 
need of psychotropic medication after TBI are, for example, 
unfavourable Glasgow Outcome Scale (GOS) [5], history 
of previous head injury [5], history of psychiatric illness 
[5, 33], unemployment before TBI [7, 17] and lower levels 
of education [7]. Thus, psychiatric sequelae after TBI are 
multifactorial seems to increase risk of late mortality. Early 
identification of psychiatric comorbidity in TBI survivors 
may be important to individualize and promote favourable 
functional and psychosocial recovery.
The very high proportion of patients with TBI combined 
with a history of psychotropic medication use, the high pro-
portion of new users among TBI survivors and the increased 
risk of late mortality highlight the need for multi-profes-
sional collaboration between fields of neurosurgery, neurol-
ogy and psychiatrics during the follow-up and rehabilita-
tion of survivors of a TBI. Early identification of potential 
psychiatric burden and early-stage psychiatric evaluation 
as the part of multidisciplinary approach in TBI patients 
might overall influence the final outcomes and necessity of 
psychiatric medicine initiation and/or psychotherapeutic late 
interventions, which would require further and more specific 
investigation. Whether these measures by a multi-profes-
sional team could improve outcomes and should be studied.
Strengths and limitations
Our study has numerous strengths. It is a multi-centre obser-
vational study including four out of the five Finnish tertiary 
ICUs treating TBI patients. This means that our study 
includes the majority of TBI patients requiring ICU treat-
ment in Finland. The referral population of the four neuro-
intensive ICU’s is approximately 3.5 million people, encom-
passing two-thirds of the Finnish population. We managed 
to do complete follow-up of the patient medication history 
as Finland has a government backed tax-funded system for 
2915Acta Neurochirurgica (2021) 163:2909–2917
1 3
drug reimbursement. Virtually all reimbursed prescriptions 
are entered into the system. Furthermore, the reimbursement 
decreases the price of drugs that could otherwise prevent 
patients of the treatment.
A limitation of the study is that we cannot exclude the 
possibility of off-label prescription of psychotropic medica-
tions, which might lead to positive bias in our study. How-
ever, negative bias might arise due to the medicine-free 
treatment (i.e. psychotherapeutic and/or supportive inter-
vention only) of certain psychiatric conditions. Also, we 
acknowledge the cultural and social influences as a potential 
factor affecting the threshold for seeking the help of psychia-
trist, and thus influencing the compliance of psychotropic 
drugs use. It should also be highlighted that we used psy-
chotropic medication as a proxy for psychiatric comorbidity. 
We did not identify specific locations of cerebral contusions. 
Thus, we could not consider the specific lesions, e.g. dam-
age to frontal and orbital lobes earlier related to psychosis 
after TBI [11, 36]. Also, we could not assess the association 
between pre-trauma socioeconomical factors and risk of psy-
chiatric sequel. The causes of death were not available and, 
thus, reasons for the increased late mortality in psychotropic 
medication users remain unclear.
Conclusions
The use of psychotropic medication in ICU-treated patients 
with TBI is common. Four out of ten patients had a history 
of psychotropic medication use prior to the TBI, and among 
survivors without prior use of psychotropic medication, 
three out of ten were later prescribed a new medication. A 
lower GCS score and a diffuse brain injury with midline shift 
were independently associated with increased odds of future 
psychotropic medication use. New psychotropic medication 
use in survivors was associated with increased odds of late 
mortality. Additional studies are required to define whether 
early identification and treatment of psychiatric sequelae 
after TBI could result in more favourable outcomes.
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